A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

Inclusion Criteria: * 18-65 years old (including boundary values), regardless of gender; * Screening requires virological , clinical or pathological evidence of hepatitis B virus infection for more than 6 months; HBsAg positive, HBeAg positive, ALT≤5×ULN at screening; * Never received nucleoside (acid) analog or interferon treatment, or previously received no more than 12 weeks of treatment but had discontinued therapy at least 6 months prior to the screening visit; * Ability to communicate effectively with researchers and understand and comply with the requirements of this study, understand and sign the informed consent form; * Male subjects with female partners who have fertility or female subjects of childbearing age are willing to voluntarily adopt effective contraceptive measures screening to within 3 months after leaving the group. Exclusion Criteria: * Pregnant (positive pregnancy test) or lactating women. * Co-infection with other viruses such as Hepatitis A Virus (HAV), Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), Human Immunodeficiency Virus (HIV), Syphilis, etc.; * History of cirrhosis or evidence of significant fibrosis or cirrhosis before or during screening; * History of hepatocellular carcinoma (HCC) or suspected HCC before or during screening.; * History of malignant tumors within the past 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection; * Subjects with other chronic liv…